(d) To the extent details are available only production of Febendazole and Morental and its salt was commenced, Production details are as follows:

Item	Name of the company	Production	
		1983-84	1984-85
(i) Morental & its salts	Pfizer Ltd.	375 Kgs.	Nil.
(ii) Fenbendazole	Hoechst	0 56 tonnes (1983)	0.96 tonnes (1984)

(e) Except for Refampicin, no other drug is specified in the First two schedules of DPCO, 1979.

(f) to (h) Do not arise.

Representation against price fixation for Multivitamins

2187. SHRI (MOLANA) ASRARUL HAQ: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that certain companies represented under Para 27 of Drugs Price Control Order, 1979 against the prices fixed for multivitamin formulations formulated in accordance with Schedule-V of Drugs and Cosmetic Act;

(b) if so, names of those companies, products, composition of each and date of representations made by each;

(c) whether any representation is still pending;

(d) if so, details and reasons thereof;

(e) names of the companies who are still selling their multivitamin products at their own prices;

(f) what are the fixed and present price of each product of each company and since when each company is marketing at their own prices;

(g) when drug formulators revised the composition and when were the prices fixed; and

(h) whether it is a fact that due to delay in fixation of prices companies made huge profits, if so, what are the details thereof?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a)to (d) After the prices of multivitamin formulations formulated in accordance with Schedule V, were announced on 12th August, 1983 a number of companies submitted their representations under Paragraph 27 of Drugs (Prices Control) Order, 1979. After decisions on their representations were taken, most of the major companies like M/s. Sarabhai Chemicals and Glaxo Laboratories complied with prices fixed by the Government. Companies like Pfizer, Sandoz, Abbot, Parke Davis, Warner Hindustan and Biological Evans are however operating with the prices allowed by the High Courts.

(e) and (f). Information would be collected and laid on the Table of the Rajya Sabha.

(g) and (h) The prices of reformulated multivitamin products were fixed on 12th August, 1983. Prices were fixed after decision on the markup to be allowed on such formulations was taken by the Government. Date of actual marketing of formulations with revised composition in accordance with Schedule V of each formulation by each company is not known and the time and efforts involved in collecting these details would not be commensurate with the results likely to be achieved.

Capacity re-endorsement of Drugs

2188. SHRIMATI MAIMOONA SULTAN: Will the Minister of INDUSTRY be pleased to state:

(a) whether Government's attention has been drawn to the news item captioned

"capacity re-endorsement" which appeared in Financial Express on the 21st November, 1985;

(b) if so, whether it is a fact that during the scrutiny of data received by Government for re-endorsement of capacity, it came to Government's notice that 432 products being manufactured by 29 drug companies are without any valid authority under I(D&R) Act.

(c) if so, names of the products based on imported bulk drugs alongwith production of each drug during the last three years, year-wise and how many of these products are being marketed by the formulators under exempted category of price control order; and

(d) what are the basis of allowing them the import without the valid authority to manufacture the formulations?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) Yes, Sir.

(b) Yes, Sir.

(c) and (d) Details of the 432 items of doubtful validity and reasons for not stopping this production have already been furnished in reply to Rajya Sabha Unstarred Question No. 771 dated 25th March, 1985. Other details are not available.

Price fixation of drugs

2189. SHRIMATI MAIMOONA SULTAN: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 187 given in the Rajya Sabha on the 18th November, 1985 and state:

(a) whether it is a fact that Government do not provide the basis or working of price fixation alongwith fixation order of prices of formulations;

(b) if so, what are the reasons for the same;

(c) whether it is a fact that due to this M|s. Abott Laboratories have been enjoying their own prices since August, 1983 and the consumers suffered;

(d) if so, who were responsible and what action was taken against them;

(e) what steps Government have taken towards the implementation of the ground on which the price fixation was quashed;

(f) whether Government have decided to provide the basis of working along with price fixation order; and

(g) if so, since when?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) and (b) Orders fixing the prices of formulations under Drugs (Prices Control) Order, 1979 are issued in accordance with the provisions of the said Order.

(c) No, Sir. The prices being enjoyed for some formulations by M|s. Abbott Laboratories are based on the judgement of the Bombay High Court.

(d) Does not arise.

(e) to (g) As a follow-up to the judgement of the Bombay High Court in the case of M|s. Abbott Laboratories, personal hearing has already been given to the company. During the hearing all the relevant factors taken into consideration while fixing the price were disclosed. Based on the details submitted by the Company, final Orders would soon be passed in this case.

Production of Anthelmintics drugs by Hoechst

2190. SHRI MIRZA IRSHADBAIG: Will the Minister of INDUSTRY be pleased to state:

(a) whether Hoechst has been licenced to produce Anthelmintics drug;

(b) if so, what is the name of the drug, licence number, date capacity and stage of manufacture permitted;

(c) whether the company has commenced the production;

(d) if so, when and what was the production from the year of commencement upto 30th October, 1985, year-wise;

(e) whether it is a fact that this drug is also being imported;